Wednesday, 27 January 2021, 7:53 am
26 January 2021 – Important advances in HIV prevention
research were announced today at the 4th
HIV Research for Prevention Conference (HIVR4P //
Virtual), convened by IAS – the International AIDS
Society.
Highlights included findings from a pair of
trials evaluating whether infusions with a broadly
neutralizing antibody (bNAb) can prevent HIV acquisition and
positive interim results from a study of long-acting
injectable pre-exposure prophylaxis (PrEP) in women. Other
announcements included promising data from a study of
islatravir as a once-monthly PrEP pill, a study warning that
many African countries are not on track to meet key UNAIDS
prevention targets, new data on global uptake of PrEP, and a
For the first time, researchers say infusions of antibodies can prevent HIV infection Source:
Corey L, et al. Abstract 1480. Presented at: HIV Research for Prevention; Jan. 27-28 and Feb. 3-4, 2021 (virtual meeting). Disclosures: Fauci reports no relevant financial disclosures. Healio could not confirm financial disclosures for Corey or Mgodi at the time of publishing. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Share
A large study in 11 countries tested whether infusions of monoclonal antibodies against HIV could protect people from infection. HIV Vaccine Trials Network
Labmade antibodies can prevent HIV infection but only if they match the virus
Jan. 26, 2021 , 10:05 AM
It has taken more than 4 years and $119 million for HIV researchers to test whether giving people infusions of antibodies made in a lab can protect them from the AIDS virus. Now, the unsatisfying answer is in: sometimes.
People who were given infusions of the monoclonal antibodies every 8 weeks had a 75% lower risk of becoming infected with HIV but only if they were exposed to strains of the virus that remained susceptible to the antibody. Researchers say the strategy, which they hoped would provide “passive immunity” in contrast to the active immunity triggered by vaccines, none of which exist for the AIDS virus is likely to be more successful with recently developed monoclonal antibodies that work agains